Verition Fund Management
OTLK icon

Verition Fund Management’s Outlook Therapeutics OTLK Stock Holding History

Verition Fund Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,680
Closed -$93.3K – 2589
2023
Q2 		$93.3K Buy
+2,680
New +$73.1K ﹤0.01% 1986

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.45B AUM 12.55% 1-Year Est. Return

Verition Fund Management's OTLK Position: Q3 2023 in Review

Verition Fund Management sold out of Outlook Therapeutics (OTLK) in Q3 2023, closing a stake of 2,680 shares — an estimated $93.3K sold.

Verition Fund Management first reported a position in OTLK in Q2 2023 and held it in 1 quarter. The position peaked at $93.3K in Q2 2023. 81 funds tracked by Wall St. Rank hold OTLK as of Q3 2023.

  • Verition Fund Management reported no remaining Outlook Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Verition Fund Management sold 2,680 Outlook Therapeutics shares in Q3 2023, an estimated $93.3K.
  • Verition Fund Management first reported a position in Outlook Therapeutics in Q2 2023 and held it in 1 quarter.
  • Verition Fund Management's Outlook Therapeutics position peaked at $93.3K in Q2 2023.
  • 81 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2023.

Based on Verition Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.